Year: 2023

Record revenue of $84.2 million, 17% year-over-year increase primarily due to 32% growth in subscription revenue; Record ARR of $295.2 million, up 27% year-over-year; Record adjusted EBITDA of $20.8 million, 24.7% Adjusted EBITDA margin; Company Increases 2023 ARR and Adjusted EBITDA Outlook, and Raises Mid-Point for Expected 2023 Revenue Range TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in Digital Intelligence (“DI”) solutions for the public and private sectors, today announced financial results for the three and nine months ending September 30, 2023. “I am pleased with Cellebrite’s third-quarter 2023 performance, which demonstrates continued business momentum and meaningful strategic progress,” said Yossi Carmil, Cellebrite’s CEO. “Against the backdrop...

CULVER CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL), a leading, global independent developer and publisher of interactive digital entertainment, announced today that it will report financial results for the third quarter ended September 30, 2023, today, November 14, 2023, after the U.S. stock market closes. Management will host a conference call and webcast today at 5:00 p.m. ET to discuss the results. Participants may listen to the live webcast and replay on the Company’s investor relations website at https://investor.snail.com/. About Snail, Inc. Snail is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. Contact:Investors:...

MIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2023. A human data readout from the ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors was presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) by Melissa A. Geller, M.D., M.S., Professor and Division Director of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Women’s Health at the University of Minnesota,...

LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal first quarter ended September 30, 2023. Recent Highlights (including post period events)Financing discussions in process with goal to provide operating runway through at least early calendar 2026, enabled by cost reductions and sales growth from adoptions by new hospital systems and independent physicians Cost cutting initiative projected to reduce payroll expense by over 35% and total SG&A by over 30% year-over-year. Now with FDA authorization of kidneyintelX.dkd, real-world outcomes data...

Five funds deliver access to innovative alpha-generating strategies on bitcoin and ether futures with cutting-edge research NEW YORK, NEW YORK and ST. PETERSBURG, FLORIDA., Nov 14 – 21Shares US LLC (“21Shares”), an affiliate of 21Shares AG, the issuer of the world’s largest suite of cryptocurrency-backed exchange traded products (ETPs), and ARK Investment Management LLC (“ARK” or “ARK Invest”), an investment adviser focused on investing in disruptive innovation, today announced the launch of a suite of five actively-managed bitcoin and ethereum futures ETFs, marking a watershed moment in the cryptocurrency investment landscape. “Together with 21Shares, ARK remains committed to increasing access to the crypto asset class, offering U.S. investors actively managed exposure to bitcoin, ether, and...

EATONTOWN, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) — Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB), is excited to announce the launch of a partnership with Kiteworks, which enables organizations to unify, track, control, and secure sensitive content communications in one platform. The Kiteworks-enabled Private Content Network allows public and private sector organizations to send, share, receive, and store sensitive content from a single platform. The new Compliance Era demands a different approach that integrates compliance and security and applies advanced governance and security tracking and controls to protect sensitive content. Kiteworks achieves this through content-based risk policy enforcement aligned with NIST CSF. “The...

JamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada.Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and JAMP Pharma Group (“JAMP Pharma”), a Canadian owned pharmaceutical organization headquartered in the Greater Montreal area, announced today that Health Canada has granted JAMP Pharma marketing authorization for AVT04, a biosimilar to Stelara® (ustekinumab) developed by Alvotech. AVT04 will be marketed under the brand name JamtekiTM. The currently approved presentations of JamtekiTM are a 45mg/0.5mL pre-filled syringe with passive safety device for subcutaneous injection (PFS-SD) and the 90mg/mL PFS-SD. This is the second biosimilar to receive marketing authorization, developed...

PrJamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. REYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Nov. 14, 2023 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and JAMP Pharma Group (“JAMP Pharma”), a Canadian owned pharmaceutical organization headquartered in the Greater Montreal area, announced today that Health Canada has granted JAMP Pharma marketing authorization for AVT04, a biosimilar to Stelara® (ustekinumab) developed by Alvotech. AVT04 will be marketed under the brand name JamtekiTM. The currently approved presentations of JamtekiTM are a 45mg/0.5mL pre-filled syringe with a passive safety device for subcutaneous injection (PFS-SD) and the...

On November 16, Terranet AB (publ) will release its Interim Report for the third quarter 2023. On the same day at 10 a.m. CET, the company’s CEO Magnus Andersson and CFO Dan Wahrenberg will provide an update on the operations in a webcast. The event will be broadcasted digitally and is open to the public. The presentation will be held in English. Via the webcast, there is an opportunity to ask written questions. Link to the webcast: https://www.finwire.tv/webcast/terranet/q3-2023/ The webcast will be available on both Finwire’s and Terranet’s websites after the broadcast has finished. For more information, please contactMagnus Andersson CEO Email: magnus.andersson@terranet.se About Terranet AB (publ)  Terranet is on a mission to save lives in urban traffic.  We develop breakthrough tech solutions for Advanced Driver Assistance Systems...